Introduction
============

Albinism is an autosomal recessive inherited condition present at birth. The phenotype ranges from a complete lack of pigmentation in the skin, hair and iris, called oculocutaneous albinism (OCA), or a lack of pigmentation in the iris alone, termed ocular albinism (OA). Several independent defects can cause albinism including a complete lack of melanocytes or few pigment cells, interference in the migration of the cells to their proper location during embryo development, and failure of the cells to produce melanin due to a lack of tyrosinase or abnormalities within the cells. Albinism is associated with severe photosensitivity to ultraviolet radiation and characteristic abnormalities in the visual system include reduced vision, nystagmus, macular/foveal hypoplasia, misrouting of optic fibers at the chiasm, and greatly decreased visual acuity.

Melanin, a dark pigment, plays an important role in the eyes and brain; it occurs in two forms-black-brown known as eumelanin and yellow-red known as pheomelanin. Both forms are dependent on the activity of the tyrosinase (*TYR*) gene (mutations in *TYR* are responsible for OCA1; OMIM [203100](http://www.ncbi.nlm.nih.gov/omim/203100)). This gene, which is a copper-containing enzyme located on chromosome 11q14.3 \[[@r1]\], is expressed in melanocytes and controls the major steps in pigment production.

Mutations in the pink eyed dilution gene (*P*; or oculocutaneous albinism II \[*OCA2*\]) gene (OMIM [203200](http://www.ncbi.nlm.nih.gov/omim/203200)) cause the OCA type 2 phenotype \[[@r2]\]. The OCA2 protein is important for normal biogenesis of melanosomes \[[@r3],[@r4]\] and normal processing and transport of melanosomal proteins such as *TYR* and tyrosinase-related protein 1 (*TYRP1*) \[[@r5],[@r6]\]. It is thought to control the melanosomal pH value, thus, regulating TYR activity and melanosomal distribution \[[@r7]-[@r9]\].

OCA type 3 (OMIM [203290](http://www.ncbi.nlm.nih.gov/omim/203290)) is caused by mutations in *TYRP1*, which is located on chromosome 9p23 \[[@r10]\]. The protein, which is encoded by the brown locus, exhibits more than 50% sequence identity with tyrosinase \[[@r11]\] and shows some tyrosine hydroxylase activity; it may specifically act as 5,6-dihydroxyindole-2-carboxylic acid (DHICA) oxidase \[[@r12],[@r13]\].

Human solute carrier family 45, member 2 (*SLC45A2*/membrane-associated transporter protein \[*MATP*\]) (OMIM [606574](http://www.ncbi.nlm.nih.gov/omim/606574))---a novel malignant melanoma-associated gene mapping to chromosomal 5p13.3 located in the melanosomal membrane--- probably functions as a membrane transporter directing melanosomal protein traffic and other substances to melanosomes \[[@r14],[@r15]\].

Ocular albinism is caused by mutations in the ocular albinism I (*OA1*; or G protein-coupled receptor 143 \[*GPR143*\]) gene (OMIM [300500](http://www.ncbi.nlm.nih.gov/omim/300500)). The protein product is thought to be a melanosomal transmembrane protein \[[@r16]\]. *OA1* is expressed in eye and epidermal melanocytes.

We present a molecular analysis of *TYR, P, TYRP1, MATP* and *GPR143*, well known candidate genes for OCA and OA1 types, in 23 (OCA-22 and OA-1) South Indian families (36 affected individuals with a positive history of albinism).

Methods
=======

The study group
---------------

All participants (16 consanguineous and 7 non-consanguineous familial cases) were referred for molecular analysis by investigators from the Paediatric Clinic, Aravind Eye Hospital, Madurai, Tamil Nadu and Netra Niramay Niketan, Vivekananda Mission Asram, Chaitanyapur, West Bengal, India. The study adhered to the Declaration of Helsinki criteria and was approved by the institutional review board; an informed consent form was obtained from each patient following an explanation of the nature of the study. All the patients were diagnosed using the ophthalmologic examinations detailed in [Table 1](#t1){ref-type="table"}. Data were also obtained on other ocular conditions such as cataracts, glaucoma, and retinal disease. The controls were selected from 100 healthy individuals with no family history of ocular abnormalities.

###### Clinical details of Probands who participated in this study.

                       **Ocular region**   **Cutaneous region**                                                                                                                                                                          
  ------- ------------ ------------------- ---------------------- ----- -------------------- ---------------------------------------------------- ----------- ----------------------------- --------- ------------------- -------------- ---------
                       **Right Eye**       **Left Eye**                                                                                                                                                                                  
  5--1    7/M          NA                  NA                     Yes   Hypopigmented        NA                                                   Albinotic   Foveal Hypoplasia             \+        brown               white          Con
  11--1   24/M         NA                  NA                     Yes   Blue with gray       NA                                                   Albinotic   Foveal Hypoplasia             \-        Reddish Brown       Milky White    Con
  14--1   12/M         NA                  NA                     Yes   Hypopigmented        NA                                                   Albinotic   Foveal Hypoplasia             \-        brown               white          Con
  16--1   19/F         NA                  NA                     Yes   Hypopigmented        NA                                                   Albinotic   Foveal Hypoplasia             \-        Golden white        Milky white    Con
  17--1   6/F          2/60                2/60                   Yes   Hypopigmented        Compound Myopic Astigmatism                          Albinotic   Macular Hypoplasia            \+        Golden white        white          Con
  21--1   9/F          2/60                2/60                   Yes   Hypopigmented        Simple Myopic Astigmatism                            Albinotic   Foveal Hypoplasia             \+        brown               white          Con
  24--1   15/M         NA                  NA                     Yes   Hypopigmented        NA                                                   Albinotic   Foveal Hypoplasia             \-        white               white          Non Con
  25--1   31/M         NA                  NA                     Yes   Hypopigmented        NA                                                   Albinotic   Foveal Hypoplasia             \-        Mild silver brown   white          Non Con
  32--1   14/M         NA                  NA                     Yes   Hypopigmented        NA                                                   Albinotic   Foveal Hypoplasia             \-        Golden white        white          Non Con
  35--1   9 Months/F   UP                  UP                     Yes   Hypopigmented        Compound Hypermetropic Astigmatism                   Albinotic   Foveal Hypoplasia             \+        brown               white          Con
  39--1   6/M          6/36                4/60                   Yes   Normally Pigmented   Compound Hypermetropic Astigmatism                   Albinotic   Foveal Hypoplasia             \- (CC)   brown               white          Con
  40--1   5/M          NA                  NA                     Yes   Hypopigmented        NA                                                   Albinotic   Foveal Hypoplasia             \-        brown               white          Non Con
  41--1   3.5/M        NA                  NA                     Yes   Hypopigmented        NA                                                   Albinotic   Foveal Hypoplasia             \-        brown               white          Con
  42--1   13/M         6/24                6/18                   Yes   Hypopigmented        Simple Hypermetropic Astigmatism                     Albinotic   Foveal Hypoplasia             \+        brown               white          Con
  44--1   9/M          5/60                5/60                   Yes   Hypopigmented        Simple Hypermetropic Astigmatism                     Albinotic   Foveal Hypoplasia             \+        brown               white          Con
  46--1   11/M         6/60                6/36                   Yes   Hypopigmented        Compound & Simple Hypermetropic Astigmatism          Albinotic   Foveal Hypoplasia             \+        Golden white        Milky white    Con
  49--1   24/M         NA                  NA                     No    Hypopigmented        NA                                                   Albinotic   Foveal Hypoplasia             \-        Red with brown      white          Con
  50--1   6 Months/F   UP                  UP                     Yes   Hypopigmented        UP                                                   Albinotic   Foveal aplasia                \+        Normal              Normal white   Con
  52--1   16/F         3/60                3/60                   Yes   Hypopigmented        Simple myopic Astigmatism                            Albinotic   Foveal aplasia                \+        Golden white        white          Con
  54--1   2.5/F        UP                  UP                     Yes   Hypopigmented        Compound Hypermetropic Astigmatism                   Albinotic   Foveal Hypoplasia & Aplasia   \+        brown               white          Con
  55--1   1.5/M        4/60                4/60                   Yes   Hypopigmented        Simple Hypermetropia                                 Albinotic   Foveal Hypoplasia             \+        white               white          NC
  58--1   9/M          5/60                5/60                   Yes   Hypopigmented        Compound Hypermetropic & Simple Myopic Astigmatism   Albinotic   Foveal Hypoplasia             \+        brown               white          Con
  62--1   22/F         6/60                6/60                   Yes   Hypopigmented        Compound Hypermetropic Astigmatism                   Albinotic   Foveal aplasia                \+        brown               white          NC

In the table, M-Male; F-Female; CC-Congenital Cataract; Nys-Nystagmus; Con-Consanguineous; NC-Non Consanguineous; UP-Un Predictable (because two patients were 6 and 9 months old); NA-Not Available (Since the patients clinical details was not retrievable because they lost their follow up).

Preparation of genomic DNA
--------------------------

Approximately 5 ml of blood was collected from each proband and members of their family. Genomic DNA was prepared from peripheral blood leukocytes using the salting-out method \[[@r17]\] and dissolved in TE buffer (1 M Tris-pH 8.0; 0.5 M EDTA-pH 8.0). The DNA was quantified using a Nano spectrophotometer (NanoDrop Technologies, Inc.Wilmington, DL) and subjected to mutation screening analysis.

PCR amplification of genomic DNA
--------------------------------

The genomic DNA was amplified using PCR (MJ Research-PTC-200; Peltier Thermal cycles, Taunton, MA; Eppendorf Mastercycler, Westbury, NY) containing 50 ng of genomic DNA, 0.2 mM concentration of each primer, 200 mM dNTPS (Medox, Biotech PVT.LTD, Chennai, India), 10 mM Tris-HCL (pH 8.3), 50 mM KCL, 1.5 mM Mgcl~2~ and 0.2 U of Taq DNA polymerase (Sigma Aldrich, St. Louis, MO) in 20 ul volume reaction mix. The primer sequences for the intron-exon boundaries and exonic regions were selected for the *TYR* \[[@r18],[@r19]\], *P* \[[@r20]\], *TYRP1* \[[@r21]\], *MATP* \[[@r22]\], and *GPR143* \[[@r23]\] genes. Primer sequences are presented in [Table 2](#t2){ref-type="table"}. For all amplicons, the genomic DNA was denatured at 94 °C for 5 min followed by 28 cycles of denaturation at 94 °C for 30 s; the annealing temperature differed according to the Tm value of each primer set, extension at 72 °C for 45 s, and final extension at 72 °C for 10 min.

###### PCR primer sequences for *TYR*, *P, TYRP1, MATP*, and *GPR143*.

  **PCR primers**                                                            **PCR primer sequence (5'-3')**      **Melting temperature (°C)**   **PCR product size (bp)**
  -------------------------------------------------------------------------- ------------------------------------ ------------------------------ ---------------------------
  **Tyrosinase (*Tyr*) gene \[**[@r18]**,**[@r19]**\]**                                                                                          
  Exon 1-1                                                                   F-CAAACTGAAATTCAATAACATATAAG         63                             678
                                                                             R-GTGGACAGCATTCCTTCTCC                                               
  Exon 1-2                                                                   F-TTCAGAGGATGAAAGCTTAAGATAAA         62                             521
                                                                             R-CGTCTCTCTGTGCAGTTTGG                                               
  Exon 1-3                                                                   F-CTGGCCATTTCCCTAGAGC                59                             605
                                                                             R-CCACCGCAACAAGAAGAGTC                                               
  Exon 1-4                                                                   F-CATCTTCGATTTGAGTGCCC               60                             514
                                                                             R-CCCTGCCTGAAGAAGTGATT                                               
  Exon 1-5                                                                   F-CACCCATGTTTAACGACATCA              59                             225
                                                                             R-GCCAGTCCCAATATGGAATA                                               
  Exon 1-6                                                                   F-GACTCTTCTTGTTGCGGTGG               60                             252
                                                                             R-CCCTGCCTGAAGAAGTGATT                                               
  Exon 2                                                                     F-CCAACATTTCTGCCTTCTCC               60                             442
                                                                             R-TCAGCTAGGGTCATTGTCGAT                                              
  Exon 3                                                                     F-AGTTATAAATCAAATGGGATAATC A         60                             296
                                                                             R-ACATTTGATAGGCACCCTCT                                               
  Exon 4                                                                     F-CTGTTTCCAATTTAGTTTTATAC            55                             790
                                                                             R-TACAAAATGGCCTATGTTAAGC                                             
  Exon 5                                                                     F-TGTCTACTCCAAAGGACTGT               59                             924
                                                                             R-GGCACTTAGCTGGATGTGTT                                               
  **Pink eyed dilution (*P*) gene \[**[@r20]**\]**                                                                                               
  Exon 1                                                                     F-GAGTTCTTACTTCGA                    52                             172
                                                                             R-TAAACCCTCCCTGCCTGTTC                                               
  Exon 2                                                                     F-GGTGCAAACGTTAGTCTCAG               60                             359
                                                                             R-CCAATCTGTGTGAAGTCCAC                                               
  Exon 3                                                                     F-CTGGGAACACATACATTATT               56                             209
                                                                             R-GTGCAATGCTCAGAAACTCT                                               
  Exon 4                                                                     F-AAGCTTGCTTTGTAGCCATT               65                             300
                                                                             R-CGATGTGCGGCCACCGCTGC                                               
  Exon 5                                                                     F-GAAAAGTGTCTGAGTCTGGC               62                             177
                                                                             R-GTCCCGAAGGTGCCTGGGTT                                               
  Exon 6                                                                     F-ATTTATACCTTACTGCTCTC               58                             183
                                                                             R-TTTCAGATCTCAGCCAGGCG                                               
  Exon 7                                                                     F-GGACATGGGGTTTCTCCTGT               59                             264
                                                                             R-TGAGATGAAATGAGATTTCAC                                              
  Exon 8                                                                     F-AGATCCCAGATGGTGTCTCA               59                             213
                                                                             R-AGGTCAGACTCCTTTAAACG                                               
  Exon 9                                                                     F-AGAGGGAGGTCCCCTAACTG               63                             272
                                                                             R-ATCTCAAGCCTCCCTGACTG                                               
  Exon 10                                                                    F-CTTTCGTGTGTGCTAACTCC               57                             195
                                                                             R-ACATCTTTGAGCTGACATCC                                               
  Exon 11                                                                    F-GCAGCGCTTCATTAGGCTCA               64                             201
                                                                             R-GGCCAGAGAAGGCCCGGTTA                                               
  Exon 12                                                                    F-GTCGTTTTAATATGGTGGCC               56                             256
                                                                             R-CCTGCAGAAGCAACCTTTA                                                
  Exon 13                                                                    F-GCCTCTGTTCTACGAGCCTG               63                             231
                                                                             R-TGCCAGAACCTGGCCGCAA                                                
  Exon 14                                                                    F-TTCACGATGTGTATAGTGGG               59                             239
                                                                             R-AAGTGGAGGTGTGCGTTTAC                                               
  Exon 15                                                                    F-GATTACAGGCGTGAGCCACC               61                             293
                                                                             R-ACCCATCAACAGATACTTCC                                               
  Exon 16                                                                    F-GAGGGTGTTGCTGATATCTG               60                             260
                                                                             R-GAATGTTCTGCTGCACACCA                                               
  Exon 17                                                                    F-AGGCTCCAAGTCACAGACCG               62                             219
                                                                             R-CTTCTTGGAGAAGTGAATCAG                                              
  Exon 18                                                                    F-AGTTGCGTAGGTTATGACAC               58                             235
                                                                             R-CCCATCCAGAATGTGACAAA                                               
  Exon 19                                                                    F-GTTATGTATTTGCAGCCCCT               58                             197
                                                                             R-AATCCACCAAATACAATTGA                                               
  Exon 20                                                                    F-GAATCGGTGTGTTAACAGTG               59                             266
                                                                             R-GTAGGCTTTCTTCATTCACC                                               
  Exon 21                                                                    F-GCCTACCTTATGTTCACGTC               58                             212
                                                                             R-AATCAAAGAACAGTGGCTGG                                               
  Exon 22                                                                    F-TGGTGGGTCTGACCCTAAGT               59                             219
                                                                             R-AGGCTATGTCCAGGCTAAAG                                               
  Exon 23                                                                    F-ACAGTATGGCAGCTTCTCTG               59                             229
                                                                             R-ACTAACTGTTGCTTTGGGCT                                               
  Exon 24                                                                    F-GAGAACAGAAGCTTACCACC               55                             204
                                                                             R-GCTTAGGAACTAGACAGTTTA                                              
  Exon 25                                                                    F-CGTATCTCATGAGCTTATCC               58                             574
                                                                             R-AGCATACAATTTGAATGCTG                                               
  **Tyrosinase-related protein 1 (*TYRP1*) gene \[**[@r21]**\]**                                                                                 
  Exon 1                                                                     F-AGAAGTTCATCAGAGACATC               50                             189
                                                                             R-TCACCATCATTAATTACATT                                               
  Exon 2                                                                     F-CGTGCTTCAGTCTTCTCTACA              59                             490
                                                                             R-GCAAGGACTTATGAACTCATTC                                             
  Exon 3                                                                     F-CGCAAGGCAGATGTTTTCATG              59                             416
                                                                             R-AAGGCATCTTGTCTGTAAAGA                                              
  Exon 4                                                                     F-AGACCAAACAGAAATGAATA               47                             305
                                                                             R-AAATTCTGACTCCAAGCTATC                                              
  Exon 5                                                                     F-AAAGAGCGACAATAAGAACTC              50                             319
                                                                             R-AAAGCCTTCTCAAAGAAACTT                                              
  Exon 6                                                                     F-TTGCTATTACCTGGAAAAGTG              51                             275
                                                                             R-TGCAAAAAGCATATGAAAATG                                              
  Exon 7                                                                     F-ATACGTTGTCTTTGGAATAAT              51                             252
                                                                             R-ATACCGTGATTACTCTACTTG                                              
  Exon 8                                                                     F-TGTCCACTTTTTGGTGATAAC              50                             323
                                                                             R-ATTCAACCAGGTGGTTTTGTG                                              
  **Membrane-associated transporter protein (*MATP*) gene \[**[@r22]**\]**                                                                       
  Exon 1-1                                                                   F-AGGCTCCACGTCAAATCCAG               63                             260
                                                                             R-GGTCACATACGCTGCCTCCA                                               
  Exon 1-2                                                                   F-CAGACTCATCATGCACAGCA               58                             252
                                                                             R-ATGCCCACGAGCATCATGAC                                               
  Exon 1-3                                                                   F-CAGCATTGTGTGGTTCCTCA               58                             261
                                                                             R-GGTCAAACACATGAACATCCTC                                             
  Exon 2                                                                     F-AACGCGGATGATTCTAAAACAGGA           65                             280
                                                                             R-CTCATTGTCTGGGGAGCTGA                                               
  Exon 3-1                                                                   F-GGGAGTGTCTATGCATGAGG               65                             324
                                                                             R-GATAGAACCATACTCGTACATTCC                                           
  Exon 3-2                                                                   F-GCCCCACTTACAGAGGTTGC               63                             224
                                                                             R-CAACAAAGAGCAAGAATATTTTCCCTTG                                       
  Exon 4                                                                     F-AGCTGGCTGAGTTTCTGCAG               62                             265
                                                                             R-CCTCAACAGGTGTTAATGGAGG                                             
  Exon 5                                                                     F-AGAGGTGGAGAAGCAGAGTG               64                             236
                                                                             R-GAAGACATCCTTAGGAGAGAG                                              
  Exon 6                                                                     F-ATGAGGCACTGCCAGCTGTA               64                             286
                                                                             R-CCCAAGGCAGAGGTTCAATG                                               
  Exon 7                                                                     F-GCCCTAAATGACAGTTCCTTG              58                             326
                                                                             R-TGTGCTTCACTGTCTCTGAG                                               
  **G protein-coupled receptor 143 (*GPR143*) gene \[**[@r23]**\]**                                                                              
  Exon 1-1                                                                   F-GAGCCTGGCTCTACTGCAGGCGCT           64                             250
                                                                             R-TGCCCAGGCAGAGCGCGTGGAAGG                                           
  Exon 1-2                                                                   F-AGCCACGCAGCTCGTGCTGAGCTTCCAGCC     68                             250
                                                                             R-CCCAGGCGCTGATCAGATTCCAACCCGCG                                      
  Exon 2                                                                     F-TCATTTTTCCAAAGCAAGAAGTCAGC         66                             293
                                                                             R-GCAGGACGTGAGAACCTGCATT                                             
  Exon 3                                                                     F-GTCTACCCTGCCGTCTCAAGGATG           66                             248
                                                                             R-CGCTCAGTGCCATCTCTTATCTTCC                                          
  Exon 4                                                                     F-GTTCCAGGCAGGCCTCTGTGC              68                             229
                                                                             R-GGCTCATGTATTCCCTGCAAGACAAC                                         
  Exon 5                                                                     F-TTTCCCTTTTTGTTCTCATCCTCTTA         63                             299
                                                                             R-AGGACAACATGTGTCACTGTCTGAG                                          
  Exon 6                                                                     F-ACCTGCTTCCATTGCCTTCTCTGTC          68                             288
                                                                             R-CTTCCCTTTGGAACTTCTGGTCACG                                          
  Exon 7                                                                     F-GAAATTCTTCTCTGACTCTCCAGCATT        63                             278
                                                                             R-TGACAGAGTGAGACCTTGTCTCTGA                                          
  Exon 8                                                                     F-ATGGTCCCTTCCAAGCGAGTCC             68                             492
                                                                             R-TCACATGAGAGGTGCTGCTGAACAC                                          
  Exon 9                                                                     F-TGAAAAACTCCATGCACTGAATACT          61                             597
                                                                             R-TGCATAACTGTACATGTATTTATTTTCTTTTG                                   

Mutational analysis
-------------------

The PCR products were purified using the gel elution kit method (Bio Basic Inc., Toronto, Canada). Bi-directional DNA sequencing for known candidate genes of OCA and OA (for exon- intron boundaries and exonic regions) was performed for all the probands and affected family members. Big dye termination chemistry was employed (3130 Genetic Analyzer; Applied Biosystems, Foster City, CA). The sequencing results were compared to the gene sequences of *TYR*, *P*, *TYRP1*, *MATP*, and *GPR143* using [Finch TV](http://www.geospiza.com/Products/finchtv.shtml) and [Chromas](http://www.technelysium.com.au/chromas.html) softwares.

The presence of novel mutations that were identified in the probands was examined in 100 unrelated healthy persons with normal phenotypes to exclude the possibility of polymorphisms. All the mutations were reconfirmed by sequencing with the new PCR product. Heterozygous patients were systematically resequenced to ensure that the screening had not overlooked mutations. To compare the impact of these genes on 22 OCA samples and 1 OA sample, OCA and OA known candidate gene screening was performed for all samples.

Among the families selected, each affected individual (proband) was analyzed for sequence changes in the selected candidate genes. If a sequence change was identified that resulted in alterations in the amino acid sequence in the protein encoded by the gene, the rest of the family members were analyzed for co-segregation of the genotype.

Evolutionary conservation of human variant amino acid residues was evaluated using [Expasy](http://www.expasy.ch/) tools by alignment to pig (*Sus scrofa*), mouse (*Mus musculus*), oryla (*Oryzias latipes*), astfa (*Astyanax fasciatus*), and nemve (*Nematostella vectensis*).

Restriction enzyme cleavage analysis
------------------------------------

The presence or absence of a restriction site was used to detect the co-segregation of sequence variations in family members and the control population. Free online software ([Insilico](http://insilico.ehu.es/)) was used to identify the appropriate restriction enzyme. Restriction digestion of PCR products was performed as per the recommendations of the respective manufacturers (New England BioLabs, Beverly, MA). For 1 ug of DNA, 10 units of restriction enzyme was used and incubated at the recommended temperature overnight and analyzed using 2% pre-stained agarose gel.

Results
=======

Clinical criteria
-----------------

A summary of the available clinical data are given in [Table 1](#t1){ref-type="table"}. Few families alone lack the clinical details that include visual acuity and type of refraction error. Most patients exhibited hypopigmented iris, nystagmus, photophobia, refractive error with combined myopic or hypermetropic astigmatism, and albinotic fundus with foveal hypoplasia.

Identification of mutations
---------------------------

Bi-directional DNA sequence analysis revealed four mutations (R239W, R278X, R299H, and G419R) in OCA type I (*TYR*) and one novel mutation (G485R) in OCA type II (*P*) among 23 probands and 13 affected individuals from the 23 familial cases (recruited from 80 families). As shown in [Table 3](#t3){ref-type="table"}, four probands showed mutations in *TYR* (17.39%), and two probands expressed the same novel mutation in *OCA2* (8.69%).

###### Mutations and polymorphisms in *TYR*, *P, TYRP1, MATP*, and *GPR143*.

                                                                                              **Mutations**             
  ---------- ------------------------------------------------------------------- ------- ---- --------------- --------- ---------------------------------------------------------------
  *TYR*      55--1                                                               1            c\. 715 C\>T    R239W     I222V\*±
             35--1                                                               2            c\. 832 C\>T    R278X      
             40--1                                                               2            c\. 896 G\>A    R299H      
             24--1                                                               4            c.1255 G\>A     G419R      
             49--1                                                               1                                      I222V\*±
             32--1                                                               1 & 4                                  I222V\*±& R402Q ±
  *P*        11--1, 52--1                                                        14           c.1453 G\>A     G485R\#    
             17--1, 21--1, 24--1, 35--1, 46--1, 49--1, 54--1, 55--1, 58--1 (H)           20                             IVSXX+4 A/G\*
  *TYRP1*    25--1                                                               2                                      Arg87Arg
  *MATP*     16--1, 44--1 (h)                                                                                            
             5--1, 14--1, 17--1, 21--1, 35--1, 41--1, 52--1, 58--1, 62--1 (H)    4                                      Thr329Thr
             42--1 (h)                                                           5                                      Leu374Phe
             32--1 (H)                                                           7                                      [rs45552240](http://www.ncbi.nlm.nih.gov/snp?term=rs45552240)
  *GPR143*   50--1 (h)                                                                                                   
             24--1, 46--1, 49--1, 58--1 (h)                                                                              
             54--1, 21--1, 32--1, 52--1 (H)                                              6                              IVSV1+10C/G

In the table, \# indicates a novel homozygous mutation (PMID: 19309806); the asterisk indicates a novel polymorphism; (H) indicates Heterozygous; and (h) indicates - Homozygous. Among the 23 Albinism families, the probands from 22 OCA families shows either mutation or polymorphism except the proband from family 39--1, In *GPR143*, one SNP was observed on the OA proband alone. Among the candidate gene analysis, a novel mutant was observed on *OCA2* that was absent in 100 alleles of ethnically matched controls and could represent potential amino acid change in the gene.

In family 55, 11 members (two affected and nine unaffected) underwent bi-directional DNA sequencing analysis. The analysis revealed that the proband (55--1) was homozygous for a c.715C\>T mutation. This mutation was also identified as homozygous in the proband's maternal grandmother who had albinism. Both parents showing the normal phenotype were heterozygous for the mutation. The genotype status was further confirmed by SsiI restriction enzyme digestion of exon 2 PCR product amplified from the DNA of the proband's unaffected parents. Both parents were confirmed to be heterozygous for the c.715C\>T mutation. The maternal grandfather and grandmother were heterozygous and mutant homozygous, respectively. The remaining unaffected members of the family exhibited a wild type of the mutation. The wild type sample following SsiI restriction enzyme digestion revealed three (166 bp, 72 bp, and 14 bp) fragments, whereas the mutant sample showed only two fragments (238 bp and 14 bp), as a result of the loss of one SsiI digestion site (data not shown).

In family 35, base changes in the c.832C\>T mutation were observed in both alleles, that codon results (R278X) termination of protein synthesis in proband (35--1). Bi-directional sequence analysis of exon 2 PCR-amplified DNA of the proband's unaffected mother and maternal grandmother revealed the carrier status of (R278X) stop codon.

In family 40, a c.896G\>A transition was identified on both alleles in the proband (40--1), and the proband's unaffected father was heterozygous for the stop codon with carrier genotype.

Similarly in family 24, the c.1255G\>A transition was identified in exon 4 of the proband (24--1) as homozygous; no other family members were willing to undergo further analysis.

Interestingly, the probands from families 11 ([Figure 1A](#f1){ref-type="fig"}; V:1) and 52 ([Figure 1B](#f1){ref-type="fig"}; VII:1) were found to be homozygous for the novel mutation c.1453G\>A identified in exon 14 of the *P* gene, responsible for OCA type II. One hundred individuals with normal phenotypes were screened for this novel mutation to exclude the possibility of polymorphisms. The degree of consanguinity in both families was high, with both parents marrying first-degree relatives. The family members of pedigree 11 were not willing to participate in this study so no further analysis could be undertaken. We, therefore, have no proof of G485R inheritance in family 11 alone. However, in family 52 the diseased allele was heterozygous in the proband's unaffected father, mother, maternal grandmother, and first younger sister.

![Pedigree and chromatogram of novel mutation Gly485Arg. **A**: Pedigree obtained from family 11. **B**: Pedigree obtained from family 52. **C**: Normal genotype from control samples. **D**: Heterozygous genotype from unaffected father (V:3), mother (VI:1), maternal grandmother (V:2), and first younger sister (VII:2). **E**: Mutant genotype from both Probands (V:1) and (VII:1) from family 11 and 52. **F**: Evolutionary conservation of Gly485Arg among the other related mammalian species. The amino acid residue glycine in the 485th position shown in red are evolutionary conserved.](mv-v16-1514-f1){#f1}

Identification of polymorphisms
-------------------------------

Although bi-directional DNA sequencing revealed five different polymorphisms in the exon, intron, and 3′UTR region of *TYR, P, TYRP1, MATP*, and *GPR143*, no pathological gene mutations were detected among the selected candidate genes in a few probands. Thus, we report on the polymorphisms we identified. In the study group, two probands (55--1, 49--1) exhibited an I222V polymorphism and one proband (32--1) had I222V and R402Q polymorphisms in *TYR* (13.04%). All three probands exhibited heterozygous patterns for these SNPs in the regions analyzed. Both of the SNPs in *TYR* were not observed in any of the control samples. In *P*, the SNP IVSXX+4 A/G was observed in nine different probands (39.13%) in the heterozygous form; similarly, heterozygosity was observed in three of the 100 controls used in the analysis. In *TYRP1,* proband 25--1 (4.34%) alone showed an R87R polymorphism in one allele; this SNP was not identified in the 100 healthy controls. In *MATP*, 13 different (56.52%) probands exhibited polymorphisms. Eleven probands carried the SNP T329T (two probands were homozygous and nine probands were heterozygous). This SNP was also detected in 16 of the 100 controls. Apart from this polymorphism one proband 42-1 carried the SNP, Leu374Phe, in exon-5 and [rs45552240](http://www.ncbi.nlm.nih.gov/snp?term=rs45552240) (SNP) was observed in 32-1 on exon 7. Similarly, nine different (39.13%) probands exhibited IVSV1+10C/G polymorphisms in *GPR143* (eight probands from OCA-24--1; 46--1; 49--1; 58--1; 54--1; 21--1; 32--1; 52--1 and one proband from OA-50--1). [Table 3](#t3){ref-type="table"} represents a list of the mutations and polymorphisms.

Discussion
==========

There is an increased awareness of genetic diseases in all of the races. Identification of mutations in candidate genes will facilitate DNA-based diagnosis of albinism. Molecular analysis of pathological mutations to reveal the origin of mutated alleles in a study population is useful under certain circumstances such as understanding the nature and severity of mutations to deliver genetic counseling. We identified four known mutations in *TYR* and one novel mutation in *P* in 23 unrelated families. The clinical categorization of an individual has become more unique and complex. Clinical references are useful and are sufficiently precise for initial diagnosis and family counseling. Accurate diagnosis of most genetic disorders is only possible with candidate gene analysis. Of the four mutations identified in the patients with albinism, three were missense and one was a nonsense (termination) mutation. These mutations were mainly clustered in exons 1, 2, and 4 ([Table 3](#t3){ref-type="table"}) of *TYR*. In the entire proband sample, four of 23 (17.39%) individuals were homozygous for a *TYR* mutation; consanguinity was associated with two of these four mutations.

The R239W missense substitution in *TYR* in a patient (55--1) from family 55 with tyrosinase-negative OCA was previously reported in Japanese patients,100%, 6.25%, respectively \[[@r24],[@r25]\], and Chinese patients, 0.83% \[[@r26]\]. The 4.34% frequency we identified in our study group does not match any of these earlier findings.

In proband 35--1, the exon 2 direct sequence reveals a homozygous change, c.832C\>T, that would create a premature stop codon, R278X, resulting in a truncated and completely inactive enzyme lacking one potential copper-binding region. This mutation was previously reported in various ethnic groups Guayanan, 12.5% \[[@r27]\]; Jewish, 2.6% \[[@r7]\]; Japanese, 100%, 12.5%, 22.2%, respectively \[[@r8],[@r25],[@r28]\]; European, 2.5% \[[@r26]\]; Mexican, 0.83% \[[@r26]\]; Indian, 0.83% \[[@r26]\]; Syrian, 0.83% \[[@r26]\]; Eastern Indian, 25%, 100%, 8.3%, respectively \[[@r18],[@r29],[@r30]\]; Indian, 80% \[[@r31]\]; and Chinese, 18.75% \[[@r32]\]. The frequency of the mutation in our study, 4.34%, does not correlate with that reported in the previous studies. The fact that c.832C\>T has been reported in different ethnic groups suggests that c.832C\>T may represent a mutation hot spot in different populations.

One missense substitution, R299H, was detected in proband 40--1 despite the fact that the child was the offspring of a non-consanguineous marriage. The heterozygous missense mutation was present in the proband's unaffected father. The R299H substitution has been observed previously in Caucasian, 12.5% \[[@r33]\]; Arab-Christian, 2.6%, 1.6%, 3.3%, respectively \[[@r7],[@r26],[@r34]\]; and Chinese, 18.75% \[[@r32]\] populations. We detected a 4.34% frequency of the R299H mutation, an approximate match to that reported earlier in Arab-Christian populations \[[@r34]\]. The G419R mutation was identified in exon 4 of proband 24--1. This pathological mutation has been previously reported in Indo-Pakistani, 25% \[[@r27]\]; Caucasian, 0.83% \[[@r26]\]; Pakistani, 0.83% \[[@r26]\]; Indian, 20% \[[@r31]\] and South-Indian, 16.6% \[[@r30]\] populations. Once more, the frequency, 4.34%, of the mutation in our study patient showed no correlation with previous findings.

We identified a novel missense mutation, c.1453G \>A (G485R) in *P* of two genetically unrelated patients. In family 52, the proband's parents, maternal grandmother and first younger sister are carriers of the mutation. The finding sheds new light on the *P* gene mutation and highlights the importance of analyzing this gene in Indian patients. Our results also indicate that the frequency of mutations in the OCA2 gene in Indian patients is to some extent comparable to that seen in Caucasian patients \[[@r35]\]. The presence of this mutation in the *OCA*2 gene is the first report in an Indian patient \[[@r36]\].) A novel c.1454G\>T (p.G485V) mutation has been recently reported in a Danish population \[[@r37]\] in the same codon.

We observed one heterozygous novel SNP c.664A\>G (I222V) in *TYR* in three different patients (32--1, 49--1, 55--1). The SNP [rs34878847](http://www.ncbi.nlm.nih.gov/snp?term=rs34878847) (c.665T\>C) has been reported in the same [codon](http://albinismdb.med.umn.edu/oca1mut.html). In family 32, the proband 32--1 and his affected father were heterozygous for a c.1205G\>A transition, (R402Q), in exon 4 of *TYR*. The heterozygosity was confirmed using Hpy188I RFLP analysis, in which mutation results in the loss of one restriction site; digestion reveals 368 bp, 182 bp, 150 bp, 50 bp,and 41 bp products in wild-type samples, whereas in heterozygous individuals it produces 368 bp, 22 3bp, 182 bp, 150 bp, 50 bp, and 41 bp fragments. In both instances, products below 100 bp were not clearly visible in agarose gel electrophoresis (data not shown). R402Q, a common non- pathological polymorphism of the human tyrosinase gene, was previously reported in Caucasians \[[@r38]\]. Here, the substitution of glutamine for arginine at codon 402 results in moderate thermoinstability of the corresponding tyrosinase polypeptide \[[@r38]\].

One novel intronic SNP IVSXX+4 A/G was heterozygous in *P* from nine different probands. The [rs34509359](http://www.ncbi.nlm.nih.gov/snp?term=rs34509359) (R87R) SNP has been previously reported in *TYRP1* \[[@r39]\]. We detected the same SNP in patient 25--1 as heterozygous.

In *MATP*, we identified a common synonymous SNP [rs2287949](http://www.ncbi.nlm.nih.gov/snp?term=rs2287949), (T329T), in exon 4 as homozygous in two different patients and heterozygous in another nine patients. In the same gene, a non-synonymous SNP [rs16891982](http://www.ncbi.nlm.nih.gov/snp?term=rs16891982), (L374F), in exon 5 was homozygous in one patient ([Table 3](#t3){ref-type="table"}). Both these SNPs have been previously reported in a Turkish population and an East Indian population \[[@r40],[@r41]\]. L374 significantly increases the possibility of having black hair and, thus, may be considered a future marker for the prediction of black hair color \[[@r42]\]. In the MATP coding sequence, one 3′UTR SNP, [rs45552240](http://www.ncbi.nlm.nih.gov/snp?term=rs45552240), was heterozygous in patient 32--1.

In *GPR143,* the intronic SNP [rs3788938](http://www.ncbi.nlm.nih.gov/snp?term=rs3788938) was heterozygous in four patients and homozygous in five others.

Taken together, our results indicate that six probands harbored five mutations (four reported and one novel in two probands) and that more than half of affected individuals who were tested (29 among 36) exhibited no apparent pathological mutations in the selected candidate genes. However, homozygous and heterozygous polymorphisms were distributed among the selected candidate genes across most of those with the disease, except one patient (39--1) who showed normal iris pigmentation. The prevalence of inherited ophthalmological diseases in our study is associated with the high rate of consanguineous marriage that we observed. Our study contributes to the development of mutation detection methods for OCA and OA in South Indian families. The identification of prevalent or novel alterations in candidate genes will shed new light on studies of expression analysis and may reveal alterations in mutated alleles suitable for further functional studies. Further analyses are needed to provide insight into the structure-function relationships of mutations involved in the candidate genes for albinism.
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